WO2004048394A1 - Phosphinic acid analogs of glutamate - Google Patents

Phosphinic acid analogs of glutamate Download PDF

Info

Publication number
WO2004048394A1
WO2004048394A1 PCT/CH2003/000770 CH0300770W WO2004048394A1 WO 2004048394 A1 WO2004048394 A1 WO 2004048394A1 CH 0300770 W CH0300770 W CH 0300770W WO 2004048394 A1 WO2004048394 A1 WO 2004048394A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
compound
methyl
enzyme
composition
Prior art date
Application number
PCT/CH2003/000770
Other languages
French (fr)
Inventor
Fridtjof Schröder
Marie-Claude Fournie-Zaluski
Andreas Natsch
Original Assignee
Givaudan Sa
Pharmaleads Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Givaudan Sa, Pharmaleads Sa filed Critical Givaudan Sa
Priority to AU2003280271A priority Critical patent/AU2003280271A1/en
Publication of WO2004048394A1 publication Critical patent/WO2004048394A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • This invention is concerned with compounds useful for the prevention or suppression of human malodour, in particular human axillary malodour.
  • Fatty acids in particular short chain, branched fatty acids are known to play a role in axillary malodour, and are particularly foul smelling components of stale sweat.
  • PCT/CH02/00262 the applicant has disclosed an enzyme that mediates in a process of transforming odourless compounds found in sweat into these malodorous fatty acids.
  • this co-pending application there is also disclosed a broad class of compounds having activity as inhibitors of the enzyme.
  • R is a substituted alkyl, benzyl or allyl residue selected from the group consisting of nonyl; 4,4,4-trifluoro-propyl; 2-methyl-4-phenyl-butyl; 4-trifluoromethyl-phenyl; pentafluorophenyl; 4-halo-phenyl, wherein halo is F or Br; naphthalene-2-yl; biphenyl-2- yl; biphenyl-3-yl; or biphenyl-4-yl; 4-tert-butyl-phenyl; 5,5,7,8,8-pentamethyl-5,6,7,8- tetrahydro-naphthalene-2-yl; 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl; l,l,3,3-tetramethyl-indan-5-yl; styryl; 2,6-dimethyl-hept-J ,5-
  • Compounds of the formula (I) contain chiral atoms and as such they can exist as isomeric mixtures or they may exist as pure stereoisomers. Most preferred are compounds have an S-configuration on the carbon atom in the position alpha to the carboxyl group.
  • compounds of the present invention may interact with an enzyme thereby to reduce the enzyme's ability to cleave compounds in sweat leading to release of malodorous acids from odourless fresh sweat.
  • That enzyme described in the afore-mentioned co-pending application, was isolated from the bacteria of the genus Corynebacteria that can be found colonising the axilla, in particular certain Corynebacteria sp., more particularly Corynebacteria striatum Ax 20 which has been submitted on the 26, April 2001 to the International Depository Authority DSMZ- Deutsche Sammlung von Mikrooganismen und Zellkulturen GmbH, D-38124 Braunschweig. The Accession Number provided by the International Depository Authority is DSM 14267.
  • the enzyme was found to occur intracellularly and can be released from the cells by mechanical disruption of the cell envelope.
  • it may be isolated from cellular extracts obtained from wild-type bacterial strains, especially from strains of Corynebacteria isolated from the human axilla, in particular Corynebacterium striatum Ax 20.
  • it may be produced by recombinant means which are well known to persons skilled in the art.
  • amino acid sequence of this enzyme is set forth in SEQ ID No. 1 and a nucleic acid sequence encoding for this enzyme is set forth in SEQ ID No. 2, both of which sequences are shown below.
  • Compounds of the present invention display inhibition of the enzyme at concentrations of about 1 to 500,nanomolar more particularly from nanomolar to tens of nanomolar concentration in vitro, e.g. from 10 to 20 nanomolar. Furthermore, having regard to the lipophilicity of the residue R, the compounds are adapted to penetrate the cell walls of the enzyme-producing bacteria, as such, they are therapeutically effective in vivo.
  • the nature of the residue R appears to influence the ability of compounds to penetrate the cellular walls of different bacteria colonising the axilla and which are implicated in malodour production.
  • other strains of Corynebacteria, or bacteria of the genus Staphylococci found in the microflora of the axilla also produce related enzymes that themselves mediate in biochemical reactions wherein L-glutamine derivatives are cleaved at N ⁇ .
  • the compounds of the present invention may interfere in cellular processes of a wide variety of bacterial strains thereby resulting in the suppression or prevention of malodour from these sources.
  • the in vitro activity of the compounds as inhibitors may be measured in terms of either their IC 50 values or their Ki values, both of which measures are well known to the person skilled in the art.
  • the IC50 value provides the concentration of an inhibitor needed to reduce enzyme velocity by half at a given substrate concentration. This value is dependent on the affinity of the substrate for the enzyme which is reflected in the value K m of the substrate.
  • the Ki value may be determined for a given substrate and a given substrate concentration by measuring IC 50 and then calculating according to the following formula
  • the uptake of the compounds in bacterial cells and the inhibition of the enzyme contained therein may be measured using an assay based on stationary-phase living cells.
  • cells may be incubated along with inhibitory compound or compounds, and the substrate (i.e. the material found in sweat, which when cleaved by the enzyme forms the malodorous acids), and the release of acids may be measured at various inhibitor concentrations.
  • the substrate i.e. the material found in sweat, which when cleaved by the enzyme forms the malodorous acids
  • the release of acids may be measured at various inhibitor concentrations.
  • Compounds of the present invention may be added to any cosmetic and personal care products such as sticks, roll-ons, pump-sprays, aerosols, deodorant soaps, powders, solutions, gels, creams, sticks, balms and lotions to enhance the deodorising effect of these products.
  • a compound of the present invention may be employed in said products in amounts of about 0.01 to 0.5% by weight.
  • the above-mentioned products may comprise antibacterial agents known in the art, e.g. Triclosan.
  • the products may also comprise dermatologically acceptable ingredients such as are commonly used in these types of product. Examples of such additional ingredients include fragrances, colorants, opacifiers, buffers, antioxidants, vitamins, emulsifiers, UN absorbers, silicones and the like.
  • all products can be buffered to the desired pH.
  • a deodorant cologne may comprise ethanol and fragrance. Fragrance may be present from 1 to 10% and the ethanol can be present to make up the mass to 100%.
  • Additional ingredients in a typical ethanol-free deodorant stick may include polyols, such as propylene glycol; derivatives thereof, such as propylene-glycol-3-myristyl ether (Witconol APM); water; a surfactant such as sodium stearate; and a fragrance.
  • the polyol may be present in an amount of 30 to 40%; the derivatives of the polyol likewise may be present at about 30 to 40%; water may be present to about 10 to 20%; the surfactant may be present to 5 to 10%; and the fragrance may be present in an amount mentioned above.
  • a typical antiperspirant stick might contain as additional ingredients such as Ethylene Glycol Monostearate (e.g. from 5 to 10%); Shea butter (e.g. from 3 to 5%); Neobee 1053 (PVO International) (e.g. from about 12 to 15%); Generol 122 (Henkel) (e.g. from about 3 to 7%); Dimethicone (DC 345)(e.g. from 30 to 40%); aluminium sesquichlorohydrate (e.g. from about 15 to 20%); and a fragrance, e.g. from 1 to 10%.
  • Ethylene Glycol Monostearate e.g. from 5 to 10%
  • Shea butter e.g. from 3 to 5%
  • Neobee 1053 PVO International
  • Generol 122 He.g. from about 3 to 7%
  • Dimethicone DC 345)(e.g. from 30 to 40%)
  • aluminium sesquichlorohydrate e.g. from about 15 to 20%
  • a fragrance e
  • An antiperspirant aerosol may contain ethanol, e.g. from about 10 to 15%; zirconium aluminium tetrachlorohydrate, e.g. from about 3 to 5%; Bentone 38, e.g. from about 1 to 2%; fragrance in an amount aforementioned; and a hydrocarbon propellant, e.g. S-3, up to 100%.
  • ethanol e.g. from about 10 to 15%
  • zirconium aluminium tetrachlorohydrate e.g. from about 3 to 5%
  • Bentone 38 e.g. from about 1 to 2%
  • fragrance in an amount aforementioned
  • a hydrocarbon propellant e.g. S-3, up to 100%.
  • An antiperspirant pump composition may contain aluminium sesquichlorohydrate, e.g. from 15 to 25%; water, e.g. from 50 to 60%; Triton X-102 (Union carbide), e.g. from 1 to 3%; dimethyl Isosorbide (ICI), e.g. from 15 to 25 %; and a fragrance in an amount as aforementioned.
  • the present invention relates to the use of the compounds and/or compositions containing same for the elimination or suppression of malodour.
  • the invention also relates to compositions comprising an odour-suppressing quantity of an inhibitor of the enzyme and dermatologically acceptable vehicles that are generally well known in the art of cosmetic and personal care products.
  • the invention also provides in another of its aspects, a method of suppressing axillary malodour comprising the step of providing a composition for application to the skin of a person in need of treatment, said composition containing an inhibitor compound and dermatologically acceptable vehicle therefor, said compound being selected from one or more compounds described above.
  • a compound of formula (I) may be prepared according to synthetic protocols as set out in detail below with reference to Scheme 1, Scheme 2 and the Examples
  • the acrylate starting material (1) may be formed according to a method described in co- pending application PCT/CH0200262 and is set forth in Scheme 3 below.
  • alkyl, benzyl or allyl halides are either commercially available or may be formed from commonly available starting materials according to synthetic protocols known per se and set out in Scheme 2 below.
  • 0.3 g (1.7 mmol) (4,4,4-trifiuoro-butyl)-phosphinic acid 3b (0.3 g, 1.7 mmol) are dissolved in HMDS (1.4 g, 8.5 mmol) at room temperature and heated at 130°C for 4 h.
  • 80°C acrylate 1 (0.7g, 1.7 mmol) is added and the reaction mixture heated at 130°C for 16 h.
  • Ethanol is added at 60°C and the mixture refluxed for 30 min. The solvents are removed under reduced pressure and the residue is dried at 50°C under high vacuum for 8 h to yield 0.9 g of 4b.
  • Example 4 Hydrolysis / detritylation of bisalkyl-phosphinoyl compounds 4 to the P-alkylated 2-(Alkyl-hvdroxy-phosphinoylmethyl)-4-carbamoyl -butyric acids 5: (Steps D and E in Scheme 1)
  • the above acid (0.5g, lmmol) is solubilized in lOmL TFA. 0.35 g (2.2mmol) iPr3SiH are added via syringe. The reaction mixture is stirred for 2 h at room temperature. TFA is removed under reduced pressure and the reaction mixture co-evapofated with toluene. The crude product is dissolved in 7 ml water at 50°C and filtered over a RPC-18 syringe. The filtrate is co-evaporated with Toluene giving 0.1 g of 5 (42%).
  • Example 5 Preparation of 7-Bromomethyl-l,l,2A4-pentamethyl-l,2,3,4-tetrahydro- naphthalene ⁇ j: (Step F of Scheme 2) In a lOOmL flask equipped with thermometer, septum and a condenser 21.6 g (0.1 mol) l,l,2,4,4,7-hexamethyl-l,2,3,4-tetrahydro-naphthalene (prepared as described by Wood, T. F.; Easter, W. M., Jr.; Carpenter, M. S.; Angiolini. J. Org. Chem.28, 2248 (1963)) is heated to 170°C.
  • Example 9 Preparation of (3-phenyl-propyl)-phosphinic acid 3t: (Step L of Scheme 2) To a solution of NaH 2 PO 2 (H 2 O) (13.2 g, 0.125 mol) and allylbenzene (6.6 g, 56 mmol) in methanol (250 ml) is added triethylborane (1M in THF, 50 ml, 50 mmol) at room temperature in an open 500 ml flask. The solution is stirred for 2 h at room temperature. The reaction mixture is concentrated under reduced pressure. 100 ml saturated KHSO 4 are added to the residue followed by extraction (200, 100 and 70 ml) with ethyl acetate.
  • Step L of Scheme 2 To a solution of NaH 2 PO 2 (H 2 O) (13.2 g, 0.125 mol) and allylbenzene (6.6 g, 56 mmol) in methanol (250 ml) is added triethylborane (1M
  • Cellular extracts of Corynebacterium striatum Ax 20 are prepared by mechanical disruption and subsequent centrifugation.
  • the extract (50 ⁇ l ml corresponding to 0.2 ml initial cell culture) is added to 50 ⁇ l of Buffer A.
  • Various concentrations of the compounds of the present invention are added in a volume of 40 ⁇ l, and after 10 min preincubation at 37°C, the reaction is and amended with 10 ⁇ l of substrate (N ⁇ -lauroyl-L-glutamine, final concentration 50 ⁇ M).
  • the samples are incubated for 15 min and then the reaction is stopped by adding 75 ⁇ l of Fluorescamine (2.5 mM dissolved in Acetonitrile).
  • the resulting fluorescence resulting from derivatization of the released glutamine with fluorescamine is determined at an excitation wavelength of 381 nm and an emission wavelength of 470 nm.
  • the inhibition % is calculated.
  • the same assay is made with a recombinantly formed enzyme produced with a strain containing an expression vector comprising a nucleic acid sequence encoding for the enzyme.
  • Compounds of the present invention tested with this method show inhibitor activity in the nano-molar to tens of nano-molar range.
  • the compound 5f wherein Halo is Br has a Ki of 11 +/- 1; the compound 51 has a Ki of 20+/- 2; and the compound 5h (the biphenyl-4yl compound) has a Ki of 18+/-2 (Table A).
  • stationary phase living cells of Ax20 are harvested and resuspended in Buffer A to an optical density at 600 nm of 0.25.
  • Inhibitory compounds are added at various concentrations, and after a preincubation of 15 min, the substrate (N ⁇ -lauroyl-L-glutamine, 1 mM final concentration) is added.
  • the samples are incubated for 1 h and then extracted with MTBE and HCl and analysed for released lauric acid using capillary GC. By comparing the samples containing compounds of the present invention with control samples with bacteria and substrate only, the inhibition (%) is calculated.
  • the compounds of the present invention can cross the bacterial cell wall and cytoplasmatic membrane, and thus can have inhibitory activity in living cells at a concentration below 1 ⁇ M.
  • the microorganism identified under I. above was accompanied by:
  • This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2001 - 04 - 26 (Date of the original deposit) 1 .
  • microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).

Abstract

Inhibitors of axillary malodour having the formula[insert here Formula (I)]wherein R has the same meaning as in the specification.

Description

PHOSPHINIC ACID ANALOGS OF GLUTAMATE
This invention is concerned with compounds useful for the prevention or suppression of human malodour, in particular human axillary malodour.
It is known that fresh sweat is odourless and that odour is only formed upon contact of sweat with skin bacteria (for example bacteria of the genera of Staphylococcus and Corynebacteria ) and it is believed that odourless molecules present in sweat are degraded by bacteria colonising the axilla. It is generally accepted (Labows et. al, Cosmet. Sci Technol. Ser. (1999), 20:59-82) that highly unpleasant malodour is released from fresh sweat mainly by the Corynebacteria genus of bacteria. The principal constituents thought to be responsible for malodour include volatile steroids, volatile sulphur compounds and short-chain, branched fatty acids.
It has been suggested to treat malodour by eradicating the bacteria responsible for causing the odour. Indeed, commercially available cosmetic deodorants often contain antibacterial compounds that generally inhibit the growth of skin microflora. Antibacterial compounds currently used in deodorant products include, for example Triclosan (2,4,4'-trichloro-2'hydroxy-diphenyl-ether). However, a draw-back to the use of antibacterials is the potential for disturbing the equilibrium of the skin's natural microflora.
Fatty acids, in particular short chain, branched fatty acids are known to play a role in axillary malodour, and are particularly foul smelling components of stale sweat. In co- pending application PCT/CH02/00262 the applicant has disclosed an enzyme that mediates in a process of transforming odourless compounds found in sweat into these malodorous fatty acids. In this co-pending application there is also disclosed a broad class of compounds having activity as inhibitors of the enzyme.
Nevertheless there remains the need to find further compounds displaying good inhibitory properties with respect to the above mentioned enzyme. Accordingly, the invention provided in a first aspect a compound of formula (I)
Figure imgf000003_0001
wherein R is a substituted alkyl, benzyl or allyl residue selected from the group consisting of nonyl; 4,4,4-trifluoro-propyl; 2-methyl-4-phenyl-butyl; 4-trifluoromethyl-phenyl; pentafluorophenyl; 4-halo-phenyl, wherein halo is F or Br; naphthalene-2-yl; biphenyl-2- yl; biphenyl-3-yl; or biphenyl-4-yl; 4-tert-butyl-phenyl; 5,5,7,8,8-pentamethyl-5,6,7,8- tetrahydro-naphthalene-2-yl; 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl; l,l,3,3-tetramethyl-indan-5-yl; styryl; 2,6-dimethyl-hept-J ,5-dienyl; 2-(4-tert-Butyl- phenyl)-l -methyl-vinyl; 2-(4-Isopropyl-phenyl)-l -methyl-vinyl; l-Methyl-3-(2,2,3- trimethyl-cyclopent-3-enyl)-propenyl; 2-(4-Isobutyl-phenyl)-l -methyl- vinyl; 2-(2- isopropyl-phenyl)-l-methyl-ethenyl; 2-phenyl-ethyl; cyclohexyl-methyl; 2,2-dimethyl- propyl; 2-pentafluorophenyl-ethyl; 3-phenyl-propyl; heptyl; and 4-isopropyl-cyclohex-l- enyl.
Compounds of the formula (I) contain chiral atoms and as such they can exist as isomeric mixtures or they may exist as pure stereoisomers. Most preferred are compounds have an S-configuration on the carbon atom in the position alpha to the carboxyl group.
As stated hereinabove, compounds of the present invention may interact with an enzyme thereby to reduce the enzyme's ability to cleave compounds in sweat leading to release of malodorous acids from odourless fresh sweat. That enzyme, described in the afore-mentioned co-pending application, was isolated from the bacteria of the genus Corynebacteria that can be found colonising the axilla, in particular certain Corynebacteria sp., more particularly Corynebacteria striatum Ax 20 which has been submitted on the 26, April 2001 to the International Depository Authority DSMZ- Deutsche Sammlung von Mikrooganismen und Zellkulturen GmbH, D-38124 Braunschweig. The Accession Number provided by the International Depository Authority is DSM 14267. The enzyme was found to occur intracellularly and can be released from the cells by mechanical disruption of the cell envelope. Thus, it may be isolated from cellular extracts obtained from wild-type bacterial strains, especially from strains of Corynebacteria isolated from the human axilla, in particular Corynebacterium striatum Ax 20. In the alternative, it may be produced by recombinant means which are well known to persons skilled in the art.
The amino acid sequence of this enzyme is set forth in SEQ ID No. 1 and a nucleic acid sequence encoding for this enzyme is set forth in SEQ ID No. 2, both of which sequences are shown below.
Compounds of the present invention display inhibition of the enzyme at concentrations of about 1 to 500,nanomolar more particularly from nanomolar to tens of nanomolar concentration in vitro, e.g. from 10 to 20 nanomolar. Furthermore, having regard to the lipophilicity of the residue R, the compounds are adapted to penetrate the cell walls of the enzyme-producing bacteria, as such, they are efficaceous in vivo.
Indeed, the nature of the residue R appears to influence the ability of compounds to penetrate the cellular walls of different bacteria colonising the axilla and which are implicated in malodour production. For example, other strains of Corynebacteria, or bacteria of the genus Staphylococci found in the microflora of the axilla also produce related enzymes that themselves mediate in biochemical reactions wherein L-glutamine derivatives are cleaved at Nα. The compounds of the present invention may interfere in cellular processes of a wide variety of bacterial strains thereby resulting in the suppression or prevention of malodour from these sources.
The in vitro activity of the compounds as inhibitors may be measured in terms of either their IC50 values or their Ki values, both of which measures are well known to the person skilled in the art. As is well known, the IC50 value provides the concentration of an inhibitor needed to reduce enzyme velocity by half at a given substrate concentration. This value is dependent on the affinity of the substrate for the enzyme which is reflected in the value Km of the substrate. In this way, the Ki value may be determined for a given substrate and a given substrate concentration by measuring IC50 and then calculating according to the following formula
ICso
Kι =
Figure imgf000005_0001
The uptake of the compounds in bacterial cells and the inhibition of the enzyme contained therein may be measured using an assay based on stationary-phase living cells. Thus, cells may be incubated along with inhibitory compound or compounds, and the substrate (i.e. the material found in sweat, which when cleaved by the enzyme forms the malodorous acids), and the release of acids may be measured at various inhibitor concentrations. By comparing IC50 values obtained with the living cells with the IC50 values obtained with the isolated enzyme, the ease of penetration of the compounds into the bacterial cells can be assessed.
Compounds of the present invention may be added to any cosmetic and personal care products such as sticks, roll-ons, pump-sprays, aerosols, deodorant soaps, powders, solutions, gels, creams, sticks, balms and lotions to enhance the deodorising effect of these products. Preferably, a compound of the present invention may be employed in said products in amounts of about 0.01 to 0.5% by weight.
The above-mentioned products, in addition to the inhibitors, may comprise antibacterial agents known in the art, e.g. Triclosan. The products may also comprise dermatologically acceptable ingredients such as are commonly used in these types of product. Examples of such additional ingredients include fragrances, colorants, opacifiers, buffers, antioxidants, vitamins, emulsifiers, UN absorbers, silicones and the like. As is also well known, all products can be buffered to the desired pH. In addition to the inhibitor, a deodorant cologne may comprise ethanol and fragrance. Fragrance may be present from 1 to 10% and the ethanol can be present to make up the mass to 100%.
Additional ingredients in a typical ethanol-free deodorant stick may include polyols, such as propylene glycol; derivatives thereof, such as propylene-glycol-3-myristyl ether (Witconol APM); water; a surfactant such as sodium stearate; and a fragrance. The polyol may be present in an amount of 30 to 40%; the derivatives of the polyol likewise may be present at about 30 to 40%; water may be present to about 10 to 20%; the surfactant may be present to 5 to 10%; and the fragrance may be present in an amount mentioned above.
A typical antiperspirant stick might contain as additional ingredients such as Ethylene Glycol Monostearate (e.g. from 5 to 10%); Shea butter (e.g. from 3 to 5%); Neobee 1053 (PVO International) (e.g. from about 12 to 15%); Generol 122 (Henkel) (e.g. from about 3 to 7%); Dimethicone (DC 345)(e.g. from 30 to 40%); aluminium sesquichlorohydrate (e.g. from about 15 to 20%); and a fragrance, e.g. from 1 to 10%.
An antiperspirant aerosol may contain ethanol, e.g. from about 10 to 15%; zirconium aluminium tetrachlorohydrate, e.g. from about 3 to 5%; Bentone 38, e.g. from about 1 to 2%; fragrance in an amount aforementioned; and a hydrocarbon propellant, e.g. S-3, up to 100%.
An antiperspirant pump composition may contain aluminium sesquichlorohydrate, e.g. from 15 to 25%; water, e.g. from 50 to 60%; Triton X-102 (Union carbide), e.g. from 1 to 3%; dimethyl Isosorbide (ICI), e.g. from 15 to 25 %; and a fragrance in an amount as aforementioned.
All percentages mentioned above are in wt %.
Accordingly, the present invention relates to the use of the compounds and/or compositions containing same for the elimination or suppression of malodour. The invention also relates to compositions comprising an odour-suppressing quantity of an inhibitor of the enzyme and dermatologically acceptable vehicles that are generally well known in the art of cosmetic and personal care products.
The invention also provides in another of its aspects, a method of suppressing axillary malodour comprising the step of providing a composition for application to the skin of a person in need of treatment, said composition containing an inhibitor compound and dermatologically acceptable vehicle therefor, said compound being selected from one or more compounds described above.
A compound of formula (I) may be prepared according to synthetic protocols as set out in detail below with reference to Scheme 1, Scheme 2 and the Examples
Scheme ]
Figure imgf000007_0001
Figure imgf000007_0002
A) 5 equivalents (eq.) HP(OTMS)2, for 2 h at 130°C.
B) 1 eq alkylphosphinic acid 3, 5 eq HMDS for 3 h at 130°C, then 1 eq acrylate 1 for 4 h at 130°C, then EtOH at 70°C. The product is obtained in quantitative yield.
C) 1 eq benzylic or allylic bromide (6 or 8), 3 eq BSA, at 25°C. The product is obtained in quantitative yield.
D) 1 N LiOH / EtOH for 1 day at 25 °C to give the product in quantitative yield.
E) 2.2 eq (iPr) SiH in TFA at 25°C for 3 h to provide compounds of the present invention. The acrylate starting material (1) may be formed according to a method described in co- pending application PCT/CH0200262 and is set forth in Scheme 3 below.
The alkyl, benzyl or allyl halides are either commercially available or may be formed from commonly available starting materials according to synthetic protocols known per se and set out in Scheme 2 below.
substituted (F) ben∑ylic α,β-unsaturated toluenes bromides 6 aldehydes
(K) (H)
(G) aliphatic aliphatic HO x allylic (I) allylic alcohols iodides 7 - H (K)
P R bromides 8 alcohols O 3 Scheme 2
(L) terminal alkenes
F) l eq Br2 at l70°C for 4 h.
G) 2 eq Pyridine, 1.2 eq PPh3, 1.2 eq Iodine at 0°C for 2 h.
H) 0.35 eq NaBH , MeOH for 2 h at 0°C, to provide the allyl alcohols in quantitative yield. I) Et2O, 0.4 eq PBr3 for 5 h at 0°C to provide allyl bromides in quantitative yields. K) 3-5 eq HP(OTMS)2 in CH2C12, for 16 h. L) 2 eq NaH2PO2(H2O), 1 eq BEt3, MeOH for 6 h at 25°C.
There now follows a series of Examples that serve to illustrate the invention.
The following compounds are formed according to the syntheses according to Example l to 9:
5a 4-Carbamoyl-2-(decyl-hydroxy-phosphinoylmethyl)-butyric acid b 4-Carbamoyl-2-[hydroxy-(4,4,4-trifluoro-butyl)-phosphinoylmethyl]-butyric acid 5c 4-Carbamoyl-2-[hydroxy-(3-methyl-5-phenyl-pentyl)-phosphinoylmethyl]-butyric acid 5d 4-Carbamoyl-2-[hydroxy-(4-trifluoromethyl-benzyl)-phosphinoylmethyl]-butyric acid 5e 4-Carbamoyl-2-(hydroxy-pentafluorophenylmethyl-phosphinoylmethyl)-butyric acid 5f 4-Carbamoyl-2-[(4-halo-benzyl)-hydroxy-phosphinoylmethyl]-butyric acid wherein halo is F or Br 5g 4-Carbamoyl-2-(hydroxy-naphthalen-2-ylmethyl-phosphinoylmethyl)-butyric acid 5h 2-(Biphenyl-2-ylmethyl-hydroxy-phosphinoylmethyl)-4-carbamoyl-butyric acid; or 2-(Biphenyl-3-ylmethyl-hydroxy-phosphinoylmethyl)-4-carbamoyl-butyric acid; or 2-(Biphenyl-4-ylmethyl-hydroxy-phosphinoylmethyl)-4-carbamoyl-butyric acid 5i 2-[(4-tert-Butyl-benzyl)-hydroxy-phosphinoylmethyl]-4-carbamoyl-butyric acid
5j 4-Carbamoyl-2-[hydroxy-(5, 5,7,8, 8-pentamethyl-5, 6,7,8-tetrahydro-naphthalen-2- ylmethyl)-phosphinoylmethyl]-butyric acid 5k 4-Carbamoyl-2-[hydroxy-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2- ylmethyl)-phosphinoylmethyl]-butyric acid 51 4-Carbamoyl-2-[hydroxy-(l,l,3,3-tetramethyl-indan-5-ylmethyl)- phosphinoylmethyl] -butyric acid 5m E-4-Carbamoyl-2-[hydroxy-(3-phenyl-allyl)-phosphinoylmethyl]-butyric acid 5n E-4-Carbamoyl-2-[(3,7-dimethyl-octa-2,6-dienyl)-hydroxy-phosphinoylmethyl]- butyric acid 5o E-2- {[3-(4-tert-Butyl-phenyl)-2-methyl-allyl]-hydroxy-phosphinoylmethyl} -4- carbamoyl-butyric acid 5p E-4-Carbamoyl-2-{hydroxy-[3-(4-isopropyl-phenyl)-2-methyl-allyl]- phosphinoylmethyl} -butyric acid 5q E-4-Carbamoyl-2-{hydroxy-[2-methyl-4-(2,2,3-trimethyl-cyclopent-3-enyl)-but-2- enyl]-phosphinoylmethyl}-butyric acid 5r E-4-Carbamoyl-2-{hydroxy-[3-(4-isobutyl-phenyl)-2-methyl-allyl]- phosphinoylmethyl} -butyric acid 5s E-4-Carbamoyl-2-{hydroxy-[3-(2-isopropyl-phenyl)-2-methyl-allyl]- phosphinoylmethyl}-butyric acid 5t 4-Carbamoyl-2-[hydroxy-(3-phenyl-propyl)-phosphinoylmethyl]-butyric acid 5u 4-Carbamoyl-2-[(2-cyclohexyl-ethyl)-hydroxy-phosphinoylmethyl]-butyric acid 5v 4-Carbamoyl-2-[(3,3-dimethyl-butyl)-hydroxy-phosphinoylmethyl]-butyric acid 5w 4-Carbamoyl-2-[hydroxy-(3-pentafluorophenyl-propyl)-phosphinoylmethyl]- butyric acid 5x 4-Carbamoyl-2-[hydroxy-(4-phenyl-butyl)-phosphinoylmethyl]-butyric acid 5y 4-Carbamoyl-2-(hydroxy-octyl-phosphinoylmethyl)-butyric acid 5z 4-Carbamoyl-2- [hydroxy-(4-isopropyl-cyclohex- 1 -enylmethyl)- phosphinoylmethylj-butyric acid
Structures of these compounds are set out below:
Figure imgf000010_0001
Figure imgf000010_0002
Figure imgf000011_0001
Figure imgf000011_0002
Figure imgf000011_0003
The following Examples are described with reference to Scheme 1 and Scheme 2.
Example 1: Preparation of 2-Hydroxyphosphinoylmethyl-4-(trityl-carbamoyl)-butyric acid ethyl ester 2: (Step A of Scheme 1)
In a 500mL flask equipped with a septum and a condenser, 25 g (0.3 mol) ammonium phosphinate and 49 g (0.3 mol) HMDS are heated under N2 at 110°C for 3.5 h. The reaction mixture is cooled to 5°C where 25 g acrylate 1 in 150 ml dichloromethane is added. The mixture is stirred for 16 h at room temperature. Work-up: 1 N HC1 and CH2C12 are added. The organic phase is washed with 1 N HC1, the combined acidic phases are re-extracted with CH2C12. The combined organic phases are dried over MgSO4, evaporated under reduced pressure and dried at 50°C under high vacuum yielding 28.8 g of phosphinic acid 2.
Yield: Quant; M.p.: 152-154°C (white solid); Purity: 89 % (31P-NMR) 31P-NMR (CDC13, 400MHz): 32.0 ppm (s). MS (ESI neg.): 957 [2M - H], 478 [M - H].
1H-NMR (CDCI3, 400MHz) : 1.2 (t, 3H), 1.8 (m, 1H), 1.9 (2H), 2.05 (m, 1H), 2.25 (m, 1H), 2.7 (m, 1H), 4.1 (q, 2H), 6.3 - 7.7 (d, 1H, P-H, J = 560 Hz), 6.9 (s, 1H, NH), 7.2 (15H, trityl-H), 8.2 (1H, P-OH).
13C-NMR (CDCI3, 400MHz): 14.2 (CH3), 28.7 (d, CH2), 30.8, 31.8 (d, P-CH2), 34.3 (s, CH2), 38.2 (CH), 61.2 (OCH2), 70.5 (Ph3C), 127.0 (3C, Trityl-CH), 127.9 (6C, Trityl- CH), 128.7 (6C, Trityl-CH), 144.6 (3C, Trityl-C), 171.0 (C=O), 174.0 (C=O).
Example 2: Preparation of 4-Carbamoyl-2-rhydroxy-(4,4,4-trifluoro-butyT)- phosphinoylmethyl -butyric acid 4b: (Step B of Scheme 1)
0.3 g (1.7 mmol) (4,4,4-trifiuoro-butyl)-phosphinic acid 3b (0.3 g, 1.7 mmol) are dissolved in HMDS (1.4 g, 8.5 mmol) at room temperature and heated at 130°C for 4 h. At 80°C acrylate 1 (0.7g, 1.7 mmol) is added and the reaction mixture heated at 130°C for 16 h. Ethanol is added at 60°C and the mixture refluxed for 30 min. The solvents are removed under reduced pressure and the residue is dried at 50°C under high vacuum for 8 h to yield 0.9 g of 4b.
Yield: 89 %; Purity: -80 % (1H-NMR)
31P-NMR (CDCI3, 400MHz): 45.3 ppm (s).
MS (ESI neg.): 670 (8% [M + NaOAc - H], 588 (100% [M - H]).
1H-NMR (CDC13, 400MHz) : 1.2 (t, 3H), 1.55 (m, 2H), 1.7 (m, 1H), 1.8 (3H), 1.95 (m,
1H), 2.15 (3H), 2.2 (m, 1H), 2.4 (m, 1H), 2.75 (m, 1H), 4.1 (q, 2H), 6.8 (s, 1H, NH), 7.2
(Trityl-H).
Whereas this synthesis is described with reference to the "R" residue relating to compound 5b (above), this synthesis is carried out for the preparation of other alkyl or aralkyl phosphinic acids whose "R" residues correspond to the compounds 5a, 5c, 5f 5i, 5n, 5t, 5u, 5v, 5w, 5x, 5y and 5z (all described above).
Example 3: Preparation of 2-rHvdroxy-(l 3-tetramethyl-indan-5-ylmethvD- phosphinoylmethyl1-4-(trityl-carbamoyl -butyric acid ethyl ester (41) (Step C of Scheme 1)
In a lOOmL flask equipped with a septum and a condenser, monoalkylphosphinic acid 2 (3g, 6.4 mmol) is dissolved in dry CH2C12 (20 ml). 5-Bromomethyl-l,l,3,3-tetramethyl- indan 61 (1.9g, 7 mmol) and BSA (3.9g, 19 mmol) are added and the mixture is stirred 72 h at 25°C. Work-up: The mixture is poured on IN HCl. The organic phase is washed with IN HCl, the combined acidic phases are re-extracted with IN HCl. The combined organic phases are dried over MgSO4, evaporated under reduced pressure and dried at 50°C under high vacuum to give 4.77 g of the bisalkylated phosphinic acid 41.
Yield: Quant; Purity: 82 % (31P-NMR)
31P-NMR (CDC13, 400MHz): 53.8 ppm (s).
MS (ESI neg.): 1329 (10% [2M - H]), 664 (100% [M - H]), 494 (30%). 1H-NMR (CDCI3, 400MHz) : 1.2 (t, 3H), 1.3 (14H), 1.7 (m, IH), 1.9 (d, 2H, P-CH2), 2.1 (m, IH), 2.25 (2H), 2.7 (m, IH), 3.0 (d, 2H, P-CH2), 4.1 (q, 2H, OCH2), 6.85 (s, IH, NH), 7.2 (15H, trityl-H), 8.4 (s, IH, P-OH).
Whereas this synthesis is described with reference to the "R" residue relating to compound 51 (above), this synthesis is carried out for the preparation of other benzylic or allylic phosphinic acids whose "R" residues correspond to the compounds 5d, 5e, 5g, 5 h, 5j, 5k, 5m, 5o, 5p, 5q, 5r and 5s (all described above).
Example 4: Hydrolysis / detritylation of bisalkyl-phosphinoyl compounds 4 to the P-alkylated 2-(Alkyl-hvdroxy-phosphinoylmethyl)-4-carbamoyl -butyric acids 5: (Steps D and E in Scheme 1)
A compound 4 (lg, 1.9 mmol) is solubilized in 9mL ethanol. 9mL IN LiOH ( 5eq) are added. The reaction mixture is stirred 3h at room temperature. IN HCl is added until pH=l and EtOH is removed under reduced pressure. The aquous residue is extracted with CH2C12. The organic layers are dried over MgSO4. Evaporation of the combined organic layers gives 0.75 g of hydrolyzed intermediate. Complete Hydrolysis is checked by 1H-NMR, the structure can be further confirmed by 31P-NMR and MS (ESI neg.). The material is subjected to detritylation without further purification:
The above acid (0.5g, lmmol) is solubilized in lOmL TFA. 0.35 g (2.2mmol) iPr3SiH are added via syringe. The reaction mixture is stirred for 2 h at room temperature. TFA is removed under reduced pressure and the reaction mixture co-evapofated with toluene. The crude product is dissolved in 7 ml water at 50°C and filtered over a RPC-18 syringe. The filtrate is co-evaporated with Toluene giving 0.1 g of 5 (42%).
All of the compounds 5 described above are obtained with purities: 85-90%) (3IP-NMR). Physical dates of some of the compounds 5 are given in Table A below.
Example 5: Preparation of 7-Bromomethyl-l,l,2A4-pentamethyl-l,2,3,4-tetrahydro- naphthalene όj: (Step F of Scheme 2) In a lOOmL flask equipped with thermometer, septum and a condenser 21.6 g (0.1 mol) l,l,2,4,4,7-hexamethyl-l,2,3,4-tetrahydro-naphthalene (prepared as described by Wood, T. F.; Easter, W. M., Jr.; Carpenter, M. S.; Angiolini. J. Org. Chem.28, 2248 (1963)) is heated to 170°C. 16 g (0.1 mol) Bromine is added and the reaction mixture is stirred for 5 h at 170°C. The content of the flask is fractionated over a Nigreux column (110°C) giving 17 g (58%) 6j as a colorless liquid.
Yield: 58%; GC-purity: 71%
GC/MS: 294 / 296 (5%, [M]+), 279 / 281 (10%, [M - CH3]+), 215 (100%, [M - Br]+,
201 (65%, [M - CH2Br ), 157 (55%).
1H-ΝMR (CDC13, 400MHz) : 0.95 (d, 3H), 1.05 (s, 3H), 1.25 (s, 3H), 1.3 (s, 3H), 1.35
(s, 3H), 1.4 (dd, IH, A), 1.65 (dd, IH, B), 1.85 (m, IH, CH), 4.5 (s, 2H, CH2Br), 7.15
(d, IH, Ar-H), 7.25 (d, IH, Ar-H), 7.35 (s, IH, Ar-H).
13C-NMR (CDCI3, 400MHz): 16.8 (CH3), 25.0 (CH3), 28.5 (CH3), 31.9 (CH3), 32.3
(CH3), 34.3 (CH2), 34.4 (C), 34.5 (CH), 37.8 (C), 43.5 (CH2Br), 126.2, 127.0, 127.7
(Ar-CH), 134.7, 145:2, 146.5 (Ar-C).
Example 6: Preparation of (5-Iodo-3-methyl-pentyl)-benzene 7c: (Step G of Scheme 2)
5 g (28 mmol) Phenoxanol (3-Methyl-5-phenyl-pentan-l-ol) are dissolved in 200 ml dichloromethane under nitrogen and stirring. Triphenylphosphine (8.8 g, 34 mmol) and 4.2 g (53 mmol) pyridine are added at 25°C. At 0°C iodine (8.5 g, 34 mmol) is added. After 2 h stirring at 0°C the reaction mixture is poured on ice-cooled 1 N HCl and extracted with dichloromethane. The combined organic phases are washed with 10% Na2S2O3, sat. NaHCO3 and sat. NaCl. Drying over MgSO4 and evaporation gives 17g of a residue which is triturated with hexane and filtered over a 5 cm Silicagel pad. The filtrate is evaporated under reduced pressure and dried under high vacuum giving 7.1 g of 7c as an colorless oil.
Yield: 88%; Purity: > 95% (GC, NMR) GC/MS: 288 (5%, [M]+), 161 (10%, [M- I]+),
119 (5%), 105 (20%, [PhCH2CH2]+), 91(100%, [[PhCH2]+).
1H-NMR (CDC13, 400MHz) : 0.95 (d, 3H, CH3), 1.45 (m, IH), 1.6 (3H), 1.9 (m, IH),
2.6 (2H, PhCH2), 3.2 (2H, CH2I), 7.2 (5H, ArH).
13C-NMR (CDCI3, 400MHz): 4.9 (CH2), 18.7 (CH3), 33.3 (CH2), 33.7 (CH3), 38.2
(CH2), 40.9 (CH2), 125.8, 128.3, 128.4 (ArCH), 142.5 (ArC).
Example 7: Preparation of E-l-(3-Bromo-2-methyl-propenyl)-4-tert-butyl-benzene 80: (Steps H and I of Scheme 2)
20 g (0.1 mol) E-3-(4-tert-Butyl-phenyl)-2-methyl-propenal (prepared as described in US 4435585) is added to a stirred solution of 1.2 g (32 mmol) of sodium borohydride in 20 ml of methanol at 0°C. After 2 h at room temperature quantitative conversion is checked by TLC. The reaction mixture is poured onto 40 ml saturated sodium chloride and extracted with tert-butyl methyl ether. Drying over magnesium sulfate and evaporation of the solvent gives the crude allylic alcohol (19.2 g, 94%), which is transferred to the following bromination without further purification. 5 g (24 mmol) of the crude allylic alcohol is dissolved in 35 ml of dry diethyl ether under nitrogen. At 0°C phosphorus tribromide (0.95 ml, 10 mmol) is added via syringe. The reaction is stirred at 0°C for 4 h, poured onto ice and extracted three times with diethyl ether. The organic layer is washed with saturated NaHCO3 and dried over MgSO . The solvent is removed under reduced pressure giving the crude allylic bromide 5.7 g of 80.
Yield: 5.7 g (87% from the aldehyde); Purity: > 95% (GC, NM )
GC/MS: 266 / 268 (3%, [M]+), 251 (1%, [M - CH3]+), 188 (25%, [M - Br]+), 173 (55%,
[M - Br - CH3]+), 157 (10%), 131 (55%), 115 (22%), 91 (16%), 57 (100%).
Η-NMR (CDCI3, 400MHz) : 1.3 (s, 9H, tBu-CH3), 2.0 (s, 3H, CH3), 4.15 (s, 2H,
CH2Br), 6.6 (s, IH, =CH), 7.22 (d, 2H, Ar-H), 7.35 (s, 2H, Ar-H).
13C-NMR (CDCI3, 400MHz): 16.6 (CH3), 31.3 (3C, tBu-CH3), 34.6 (tBu-C), 42.6
(CH2), 125.2, 128.7 (ArCH), 130.0 (=CH), 133.7, 134.0 (Ar-C), 150.2 (=C) Example 8: Preparation of (3 -Dimethyl-octa-2,6-dienvD-phosphinic acid 3n: ("Step K of Scheme 2)
In a 750mL flask equipped with septum, thermometer and condenser, ammonium phosphinate (25 g, 0.3 mol) and HMDS (51 g, 0.32 mmol) are'heated under N2 at 110°C for 3 h. The reaction mixture is cooled to 0°C. 300 mL dried CH2C12 are added followed by the addition of geranyl bromide (13.1 g, 60 mmol). The mixture is stirred for 16 h at room temperature. 12 g methanol are added and the fine suspension is filtered over a double filter layer. The filtrate is concentrated under reduced pressure. 10% Na2CO3 and tert-butyl methyl ether are added, the phases are separated and the alkaline layer purified with tert-butyl methyl ether. The alkaline layer is treated with cone. HCl until pH - 1 and is 3 times extracted with dichloromethane. Drying of the dichloromethane layer over MgSO4 and evaporation give 13.7 g (81%) of 3n as an orange oil.
Yield: 13.7 g (81%); Purity: 77% (31P-NMR)
31P-NMR (CDC13, 400MHz): 34.9 ppm (s).
MS (ESI neg.): 403 (10% [2M - H]+), 201 (100%, [M-H]+).
1H-NMR (CDCI3, 400MHz): 1.2 (d, IH), 1.6 (s, 3H, CH3), 1.6 (6H, 2 CH3), 2.1 (4H,
CH2CH2), 2.6 (dd, 2H, P-CH2), 5.1 (IH, =CH), 5.15 (IH, =CH), 6.22 and 7.6 (d, IH, J =
548 Hz, P-H), 11.8 (s, IH, POH).
13C-NMR (CDCI3, 400MHz): 16.5 (CH3), 17.6 (CH3), 25.6 (CH3), 26.4 (CH2), 30.4 and
29.5 (d, P-CH2), 39.7 (CH2), 110.5 (=CH), 123.7 (=CH), 131.7 (=C), 141.9 (=C).
Example 9: Preparation of (3-phenyl-propyl)-phosphinic acid 3t: (Step L of Scheme 2) To a solution of NaH2PO2(H2O) (13.2 g, 0.125 mol) and allylbenzene (6.6 g, 56 mmol) in methanol (250 ml) is added triethylborane (1M in THF, 50 ml, 50 mmol) at room temperature in an open 500 ml flask. The solution is stirred for 2 h at room temperature. The reaction mixture is concentrated under reduced pressure. 100 ml saturated KHSO4 are added to the residue followed by extraction (200, 100 and 70 ml) with ethyl acetate. To the combined ethyl acetate phases are added 40 ml 10% Na CO3. Under vigorous stirring and dropwise addition of cone. NaOH the biphasic mixture is adjusted to pH = 10. The organic phase is separated and the alkaline phase adjusted to pH = 2 by addition of cone. HCl. Extraction with chloroform (3 x 100 ml), drying of the combined organic layer over MgSO4 and evaporation gives 5.4 g of crude 3t (61%).
Yield: 61%; Purity: 84% (31P-NMR)
31P-NMR (CDC13, 400MHz): 38.2 ppm (s).
MS (ESI neg.): 265 (6% [M - H + NaOAc ), 183 (100%, [M-H]+).
1H-NMR (CDCI3, 400MHz) : 1.75 (m, 2H, CH2), 1.9 (m, 2H, CH2), 2.76 (t, 2H,
PhCH2), 6.4 and 7.7 (d, IH, J = 548 Hz, P-H), 11.4 (s, IH, POH).
Table A: Ki(nM) value and physical datas
Figure imgf000018_0001
Example 10 : Measuring inhibitory activity
Cellular extracts of Corynebacterium striatum Ax 20 (DSM 14267) are prepared by mechanical disruption and subsequent centrifugation. The extract (50 μl ml corresponding to 0.2 ml initial cell culture) is added to 50 μl of Buffer A. Various concentrations of the compounds of the present invention are added in a volume of 40 μl, and after 10 min preincubation at 37°C, the reaction is and amended with 10 μl of substrate (Nα-lauroyl-L-glutamine, final concentration 50 μM). The samples are incubated for 15 min and then the reaction is stopped by adding 75 μl of Fluorescamine (2.5 mM dissolved in Acetonitrile). The resulting fluorescence resulting from derivatization of the released glutamine with fluorescamine is determined at an excitation wavelength of 381 nm and an emission wavelength of 470 nm. By comparing the samples containing compounds of the present invention with control samples with enzyme and substrate only, the inhibition (%) is calculated. Alternatively, the same assay is made with a recombinantly formed enzyme produced with a strain containing an expression vector comprising a nucleic acid sequence encoding for the enzyme. Compounds of the present invention tested with this method show inhibitor activity in the nano-molar to tens of nano-molar range. For example, the compound 5f wherein Halo is Br has a Ki of 11 +/- 1; the compound 51 has a Ki of 20+/- 2; and the compound 5h (the biphenyl-4yl compound) has a Ki of 18+/-2 (Table A).
In order to evaluate enzyme activity in intact cells, stationary phase living cells of Ax20 are harvested and resuspended in Buffer A to an optical density at 600 nm of 0.25. Inhibitory compounds are added at various concentrations, and after a preincubation of 15 min, the substrate (Nα-lauroyl-L-glutamine, 1 mM final concentration) is added. The samples are incubated for 1 h and then extracted with MTBE and HCl and analysed for released lauric acid using capillary GC. By comparing the samples containing compounds of the present invention with control samples with bacteria and substrate only, the inhibition (%) is calculated. By comparing the inhibitory capacity of the compounds on the isolated enzyme with the values obtained using intact cells, the relative uptake of the compounds by the cells can be assessed. The compounds of the present invention can cross the bacterial cell wall and cytoplasmatic membrane, and thus can have inhibitory activity in living cells at a concentration below 1 μM. BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNIHON OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE
INTERNATIONAL FORM
Givaudan SA 1214 Vernier Switzerland
RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page
I. IDENTIFICATION OF THE MICROORGANISM
Identification reference given by the DEPOSITOR: Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: Ax 20
DSM 142 S7
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONO C DESIGNATION
The microorganism identified under I. above was accompanied by:
(X ) a scientific description
(X ) a proposed taxonomic designation
(Mark with a cross where applicable).
III. RECEIPT AND ACCEPTANCE
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2001 - 04 - 26 (Date of the original deposit)1.
IV. RECEIPT OF REQUEST FOR CONVERSION
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).
V. INTERNATIONAL DEPOSITARY AUTHORITY
Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of person(s) having the power to represent the MIKROORGANISMEN UND ZELL ULTUREN GmbH International Depositary Authority or of authorized official(s):
Address: Mascheroder Weg lb D-38U4 Braunschweig ex. ty*,- *
Date: 2001 - 04 - 30
' Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired. Form DSMZ-BP/4 (sole page) 0196 Sequence listing part of description
SEQUENCE LISTING
110> Givaudan SA
P armaLeads SA
<120> Organic compounds
<130> 30073 PCT
<150> GB 0227363.9 <151> 2002-11-25
<160> 2
<170> Patentln version 3.1
<210> 1
<211> 399
<212> PRT
<213> Corynebacterium striatum
<400> 1
Ala Gin Glu Asn Leu Gin Lys He Val Asp Ser Leu Glu Ser Ser Arg 1 5 10 15
Ala Glu Arg Glu Glu Leu Tyr Lys Trp Phe His Gin His Pro Glu Met 20 25 30
Ser Met Gin Glu His Glu Thr Ser Lys Arg He Ala Glu Glu Leu Glu 35 40 45
Lys Leu Gly Leu Glu Pro Gin Asn He Gly Val Thr Gly Gin Val Ala 50 55 60
Val He Lys Asn Gly Glu Gly Pro Ser Val Ala Phe Arg Ala Asp Phe 65 70 75 80
Asp Ala Leu Pro He Thr Glu Asn Thr Gly Leu Asp Tyr Ser Ala Asp 85 90 95
Pro Glu Leu Gly Met Met His Ala Cys Gly His Asp Leu His Thr Thr 100 105 110
Ala Leu Leu Gly Ala Val Arg Ala Leu Val Glu Asn Lys Asp Leu Trp 115 120 125
Ser Gly Thr Phe He Ala Val His Gin Pro Gly Glu Glu Gly Gly Gly 130 135 140
Gly Ala Arg His Met Val Asp Asp Gly Leu Ala Glu Lys He Ala Ala 145 150 155 160
Pro Asp Val Cys Phe Ala Gin His Val Phe Asn Glu Asp Pro Ala Phe 165 170 175 Gly Tyr Val Phe Thr Pro Gly Arg Phe Leu Thr Ala Ala Ser Asn Trp 180 185 190
Arg He His He His Gly Glu Gly Gly His Gly Ser Arg Pro His Leu 195 200 205
Thr Lys Asp Pro He Val Val Ala Ala Ser He He Thr Lys Leu Gin 210 215 220
Thr He Val Ser Arg Glu Val Asp Pro Asn Glu Val Ala Val Val Thr 225 230 235 240
Val Gly Ser He Glu Gly Gly Lys Ser Thr Asn Ser He Pro Tyr Thr 245 250 255
Val Thr Leu Gly Val Asn Thr Arg Ala Ser Asn Asp Glu Leu Ser Glu 260 265 270
Tyr Val Gin Asn Ala He Lys Arg He Val He Ala Glu Cys Gin Ala 275 280 285
Ala Gly He Glu Gin Glu Pro Glu Phe Glu Tyr Leu Asp Ser Val Pro 290 295 300
Ala Val He Asn Asp Glu Asp Leu Thr Glu Gin Leu Met Ala Gin Phe 305 310 315 320
Arg Glu Phe Phe Gly Glu Asp Gin Ala Val Glu He Pro Pro Leu Ser 325 330 335
Gly Ser Glu Asp Tyr Pro Phe He Pro Asn Ala Trp Gly Val Pro Ser 340 345 350
Val Met Trp Gly Trp Ser Gly Phe Ala Ala Gly Ser Asp Ala Pro Gly 355 360 365
Asn His Thr Asp Lys Phe Ala Pro Glu Leu Pro Asp Ala Leu Glu Arg 370 375 380
Gly Thr Gin Ala He Leu Val Ala Ala Ala Pro Trp Leu Met Lys 385 390 395
<210> 2
<211> 1212
<212> DNA
<213> Corynebacterium striatum
<400> 2 aatcgggtca tggcacagga aaatttgcaa aagattgtag atagtctcga gtcctcccgc 60 gcggaacgcg aagaactgta caagtggttc caccagcacc cggaaatgtc gatgcaggag 120 cacgaaacct ccaagcgcat cgcagaagag ctagagaagc tcggccttga gccgcagaac 180 atcggcgtga ccgggcaggt cgcggtaatc aagaacggtg aaggcccgag cgtggcattt 240 cgtgcggact ttgatgcctt gccgatcacc gagaacaccg ggctggatta ctcggcggat 300 cccgagctgg gcatgatgca cgcctgcggc cacgatttgc acaccactgc cctactcggc 360 gcggtgcgcg cgctggtgga gaacaaggac ctgtggtccg gcaccttcat cgcagtccac 420 caacccggtg aggaaggcgg cggcggggcc cgccacatgg tggacgacgg cctcgcggag 480 aagatcgcgg cgccggatgt gtgtttcgcc cagcacgtgt tcaacgaaga ccccgccttt 540 ggctacgtgt tcacccccgg ccggtttcta acggcggcgt cgaactggag aatccacatc 600 cacggcgagg gcggacacgg ttcccgtccg cacctgacca aggacccgat tgtggtggcg 660 gcctcgatca ttaccaagct gcagacgatt gtctcccgcg aagtcgatcc gaatgaggtc 720 gcagtggtca ccgtcggctc catcgagggc ggcaagtcca ccaactcgat cccgtacacc 780 gtcaccctcg gcgtgaacac ccgagcctcc aacgatgagσ tctccgagta cgtccagaac 840 gccatcaagc gcatcgtcat cgcggagtgc caggctgcag gcatcgaaca ggagccggaa 900 ttcgagtacc tggactcagt cccggccgtg atcaacgacg aggatctcac cgaacagctc 960 atggcgcagt tccgggagtt cttcggcgag gaccaggcgg tagagattcc gcccctgtcc 1020 ggcagcgagg actacccctt cattccgaac gcctggggcg tgccgagtgt gatgtgggga 1080 tggtccggct tcgccgcagg ttctgacgca ccgggcaatc acaccgacaa gttcgccccc 1140 gagcttccag atgccctcga acgcggcacc caggccattc tggtggccgc cgcgccctgg 1200 ttgatgaagt ga 1212

Claims

Claims
1. A compound of formula (I)
Figure imgf000024_0001
wherein R is a substituted alkyl, benzyl or allyl residue selected from the group consisting of nonyl; 4,4,4-trifluoro-propyl; 2-methyl-4-phenyl-butyl; 4- trifluoromethyl-phenyl; pentafluorophenyl; 4-halo-phenyl, wherein halo is F or Br; naphthalene-2-yl; biphenyl-2-yl, biphenyl-3-yl, or biphenyl-4-yl; 4-tert- butyl-phenyl; 5,5,7,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalene-2-yl; 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl; 1,1,3,3-tetramethyl- indan-5-yl; styryl; 2,6-dimethyl-hept-l,5-dienyl; 2-(4-tert-Butyl-phenyl)-l- methyl-vinyl; 2-(4-Isopropyl-phenyl)-l -methyl-vinyl; l-Methyl-3-(2,2,3- trimethyl-cyclopent-3-enyl)-propenyl; 2-(4-Isobutyl-phenyl)- 1 -methyl-vinyl; 2- (2-isopropyl-phenyl)-l-methyl-ethenyl; 2-phenyl-ethyl; cyclohexyl-methyl; 2,2- dimethyl-propyl; 2-pentafluorophenyl-ethyl; 3-phenyl-propyl; heptyl; and 4- isopropyl-cyclohex-1-enyl.
2. A composition comprising a body odour-suppressing quantity of a compound claimed in claim 1.
3. Composition according to claim 2 wherein the compound is present in amounts of about 0.01 to 0.5 % by weight.
4. Composition according to claim 2 or claim 3 selected from cosmetic and personal care products, in particular deo-sticks, roll-ons, pump-sprays, aerosols, deodorant soaps, powders, solutions, gels, creams, sticks, balms and lotions.
5. Use of a compound as defined by claim 1 or composition comprising a compound as defined by claim 1 to inhibit an enzyme in its ability to cleave compounds contained in sweat into short-chained, branched fatty acids, which enzyme is produced in bacteria of the genus Cotynebacteria, which bacteria has been deposited at the International Depository Authority DSMZ- Deutsche Sammlung von Mikrooganismen und Zellkulturen GmbH, D-38124 Braunschweig under the Accession Number DSM 14267.
6. Use of a compound as defined by claim 1 or composition comprising a compound as defined by claim 1 to inhibit an enzyme in its ability to cleave compounds contained in sweat into short-chained, branched fatty acids, which enzyme is defined by an amino acid sequence set forth as SEQ ID No. 1.
7. A method of suppressing axillary malodour comprising the step of providing a composition for application to a person in need of treatment, said composition containing an inhibitor compound and a dermatologically acceptable vehicle therefore, said compound being selected from one or more compound as defined by claim 1.
PCT/CH2003/000770 2002-11-25 2003-11-21 Phosphinic acid analogs of glutamate WO2004048394A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003280271A AU2003280271A1 (en) 2002-11-25 2003-11-21 Phosphinic acid analogs of glutamate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0227363A GB0227363D0 (en) 2002-11-25 2002-11-25 Organic compounds
GB0227363.9 2002-11-25

Publications (1)

Publication Number Publication Date
WO2004048394A1 true WO2004048394A1 (en) 2004-06-10

Family

ID=9948392

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2003/000770 WO2004048394A1 (en) 2002-11-25 2003-11-21 Phosphinic acid analogs of glutamate

Country Status (3)

Country Link
AU (1) AU2003280271A1 (en)
GB (1) GB0227363D0 (en)
WO (1) WO2004048394A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388129B2 (en) 2012-10-23 2016-07-12 Pharmaleads Mixed inhibitors of aminopeptidase N and neprilysin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0265412A2 (en) * 1986-10-24 1988-04-27 Monsanto Company 2-Amino-4-Phosphonyl-butanoate derivates and preparation of 2-amino-4-phosphinyl butanoic acids
WO2002092024A2 (en) * 2001-05-14 2002-11-21 Givaudan Sa Compounds and methods for inhibiting axillary malodour

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0265412A2 (en) * 1986-10-24 1988-04-27 Monsanto Company 2-Amino-4-Phosphonyl-butanoate derivates and preparation of 2-amino-4-phosphinyl butanoic acids
WO2002092024A2 (en) * 2001-05-14 2002-11-21 Givaudan Sa Compounds and methods for inhibiting axillary malodour

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388129B2 (en) 2012-10-23 2016-07-12 Pharmaleads Mixed inhibitors of aminopeptidase N and neprilysin

Also Published As

Publication number Publication date
AU2003280271A1 (en) 2004-06-18
GB0227363D0 (en) 2002-12-31
AU2003280271A8 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
JP5264236B2 (en) Human malodor control agent
WO1997030687A2 (en) Fragrance precursors
JPH0222285A (en) Phenol substituted diem-diphosphonate derivative and preparation thereof and pharmaceutical composition containing the same
EP1811034B1 (en) Compounds and method for inhibiting axillary malodour
NO169438B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE TETRAZOLIC COMPOUNDS
JP7177086B2 (en) 2,3,7-trimethyloct-6-enyl acetate and 3,7-dimethyl-2-methylene-oct-6-enyl acetate and their derivatives and their use as aroma chemicals
US7402576B2 (en) Phosphinic acid analogs of glutamate
WO2004048394A1 (en) Phosphinic acid analogs of glutamate
US8349790B2 (en) Substituted octane(ene) nitriles, methods for the synthesis thereof and uses thereof in perfumery
GB2529901A (en) Organic compounds
WO2009056756A1 (en) Substituted octane(ene) nitriles, methods for the synthesis thereof and uses thereof in perfumery
GB1599365A (en) Compounds spiro (5-isopropylbicyclo(3.1.0)hexane-2,2&#39;-oxiranes)process for the production of the compounds and process for the production of sabinene hydrates therefrom
Epstein et al. Titanium-mediated formation of 1, 2-disubstituted cyclopropanols from esters and alkenes. A new approach to the synthesis of 3, 11-dimethylnonacosan-2-one, a sex pheromone of the German cockroach
JP7036796B2 (en) Organic compounds
GB2528467A (en) Organic compounds
EP0640068A1 (en) Synthesis of cosmetic ingredient
JP3771632B2 (en) Novel β-hydroxycarboxylic acid and perfume composition containing the same
Davis et al. A new bisphosphonate reagent for the synthesis of (Z)-olefins and bis (trifluoroethyl) phosphonates
US6200254B1 (en) Macrocyclic ketones as fragrance materials and methods for making same
US5475129A (en) Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis
Rulev et al. Capto-dative acylenamines in the reactions with dialkyl hydrogen phosphites: One-pot transformation of α-formylated enamines to the esters of N, N-disubstituted α-aminoacids
US4931428A (en) 1-tert-butoxy-ω-alkenes and their use as scents
Yuan et al. Studies on organophosphorus compounds 59. Regioselective phosphorylation and formylation of propenylphosphonates—A novel and convenient route to propenylidenebisphosphonates and 1‐methoxycarbonylpropenylphosphonates
WO1993025561A1 (en) Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis
Lee et al. A One-Pot Generation of α-Chloro-α-Lithio Alkanephosphonates. A New Preparative Route to 1, 2-Epoxyalkanephosphonates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WA Withdrawal of international application
WWW Wipo information: withdrawn in national office

Ref document number: 2003280271

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: JP